Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dimitrov

Showing results (431-440 of 442) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Cell Reports|November 29, 2023
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capabilityYang Feng, Jaewon Lee, Liping Yang, et al.
Cell Reports. Medicine|September 29, 2023
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Iscience|July 25, 2022
Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domainsChuan Chen, James W Saville, Michelle M Marti, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2022
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH DomainsChuan Chen, James W Saville, Michelle M Marti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2025
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringYunji Liao, Hang Ma, Zhenyu Wang, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Cancer Discovery|May 22, 2021
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing SarcomaHai-Feng Zhang, Christopher S Hughes, Wei Li, et al.
Cancer Discovery|April 13, 2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancersHai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang, et al.
Pageof 45

Showing results (431-440 of 442) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Cell Reports|November 29, 2023
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capabilityYang Feng, Jaewon Lee, Liping Yang, et al.
Cell Reports. Medicine|September 29, 2023
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Iscience|July 25, 2022
Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domainsChuan Chen, James W Saville, Michelle M Marti, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2022
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH DomainsChuan Chen, James W Saville, Michelle M Marti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2025
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringYunji Liao, Hang Ma, Zhenyu Wang, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Cancer Discovery|May 22, 2021
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing SarcomaHai-Feng Zhang, Christopher S Hughes, Wei Li, et al.
Cancer Discovery|April 13, 2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancersHai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang, et al.
Pageof 45